AngioDynamics (NASDAQ:ANGO) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a buy rating in a research report report published on Saturday.

Several other equities analysts have also commented on ANGO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. HC Wainwright upped their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Zacks Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Finally, Canaccord Genuity Group boosted their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, AngioDynamics presently has an average rating of “Hold” and an average target price of $19.50.

AngioDynamics Stock Performance

AngioDynamics stock opened at $15.75 on Friday. AngioDynamics has a 1 year low of $9.06 and a 1 year high of $16.29. The firm’s 50-day moving average is $13.96 and its 200-day moving average is $12.05. The company has a market cap of $650.95 million, a P/E ratio of -18.10 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts predict that AngioDynamics will post -0.25 earnings per share for the current year.

Insider Transactions at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. This represents a 26.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 6.00% of the stock is owned by corporate insiders.

Institutional Trading of AngioDynamics

A number of institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in shares of AngioDynamics in the second quarter valued at approximately $64,000. Bank of America Corp DE acquired a new position in shares of AngioDynamics during the second quarter valued at approximately $4,490,000. Gallagher Fiduciary Advisors LLC bought a new stake in AngioDynamics during the second quarter worth approximately $589,000. Hsbc Holdings PLC bought a new stake in AngioDynamics during the second quarter worth approximately $356,000. Finally, Canada Pension Plan Investment Board acquired a new stake in AngioDynamics in the second quarter worth approximately $428,000. 89.43% of the stock is owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.